RECRUITINGINTERVENTIONAL
Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
Reducing Fatigue in People With Multiple Sclerosis by Treatment With Transcutaneous Electrical Nerve Stimulation
About This Trial
The objective of the randomized, sham-controlled trial will be to evaluate the effectiveness of treatment with transcutaneous electrical nerve stimulation (TENS) at reducing the level of fatigue experienced by people with MS.
Who May Be Eligible (Plain English)
Who May Qualify:
- Men and women18-65 yrs
- Able to read, understand, and speak English to ensure safe participation in the project
- Clinical diagnosis of relapsing-remitting MS
- Self-reported difficulty with walking
- On stable doses of Ampyra, provigil, or other symptomatic-treating medications
- No relapse or systemic steroids within the last 30 days
- Able to arrange transportation to the Boulder campus
Who Should NOT Join This Trial:
- Vision or hearing problems that have not been corrected
- Problems with sensations to temperature, pressure, or pain
- Any arm or leg problems that would influence the ability to hold a weight
- Surgery to the arms or legs that continues to bother the participant
- Metal implants
- Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy
- History of head injury or stroke
- Taking antidepressants, anticholinergics, stimulants, sedatives, cannabis, illicit drugs or medications to treat herpes or neurologic pain.
- Diagnosis of diabetes mellitus
- Poorly controlled hypertension
- History of seizure disorders
- ≥2 alcoholic drinks/day, or present history (last 6 months) of drug abuse
- Spasticity that requires the individual to change intended activities more often than once a week
- Skin diseases or sensation problems in the legs or hands that influences some activities more often than once a week
- Inability to attend exercise sessions 3 days per week for 6 weeks
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Men and women18-65 yrs
* Able to read, understand, and speak English to ensure safe participation in the project
* Clinical diagnosis of relapsing-remitting MS
* Self-reported difficulty with walking
* On stable doses of Ampyra, provigil, or other symptomatic-treating medications
* No relapse or systemic steroids within the last 30 days
* Able to arrange transportation to the Boulder campus
Exclusion Criteria:
* Vision or hearing problems that have not been corrected
* Problems with sensations to temperature, pressure, or pain
* Any arm or leg problems that would influence the ability to hold a weight
* Surgery to the arms or legs that continues to bother the participant
* Metal implants
* Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy
* History of head injury or stroke
* Taking antidepressants, anticholinergics, stimulants, sedatives, cannabis, illicit drugs or medications to treat herpes or neurologic pain.
* Diagnosis of diabetes mellitus
* Poorly controlled hypertension
* History of seizure disorders
* ≥2 alcoholic drinks/day, or present history (last 6 months) of drug abuse
* Spasticity that requires the individual to change intended activities more often than once a week
* Skin diseases or sensation problems in the legs or hands that influences some activities more often than once a week
* Inability to attend exercise sessions 3 days per week for 6 weeks
Treatments Being Tested
DEVICE
Transcutaneous electrical nerve stimulation
Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
Locations (1)
University of Colorado
Boulder, Colorado, United States